247 related articles for article (PubMed ID: 21084819)
41. Immunohistochemical features associated with sensitivity to lapatinib-plus-capecitabine and resistance to trastuzumab in HER2-positive breast cancer.
Cha Y; Han SW; Seol H; Oh DY; Im SA; Bang YJ; Park IA; Han W; Noh DY; Kim TY
Anticancer Res; 2014 Aug; 34(8):4275-80. PubMed ID: 25075058
[TBL] [Abstract][Full Text] [Related]
42. A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer.
Martin M; Bonneterre J; Geyer CE; Ito Y; Ro J; Lang I; Kim SB; Germa C; Vermette J; Wang K; Wang K; Awada A
Eur J Cancer; 2013 Dec; 49(18):3763-72. PubMed ID: 23953056
[TBL] [Abstract][Full Text] [Related]
43. Safety and efficacy of neratinib in combination with capecitabine in patients with metastatic human epidermal growth factor receptor 2-positive breast cancer.
Saura C; Garcia-Saenz JA; Xu B; Harb W; Moroose R; Pluard T; Cortés J; Kiger C; Germa C; Wang K; Martin M; Baselga J; Kim SB
J Clin Oncol; 2014 Nov; 32(32):3626-33. PubMed ID: 25287822
[TBL] [Abstract][Full Text] [Related]
44. Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trial.
Joensuu H; Kellokumpu-Lehtinen PL; Huovinen R; Jukkola-Vuorinen A; Tanner M; Kokko R; Ahlgren J; Auvinen P; Paija O; Helle L; Villman K; Nyandoto P; Nilsson G; Pajunen M; Asola R; Poikonen P; Leinonen M; Kataja V; Bono P; Lindman H
J Clin Oncol; 2012 Jan; 30(1):11-8. PubMed ID: 22105826
[TBL] [Abstract][Full Text] [Related]
45. Lapatinib and metronomic capecitabine combination in an HER2-positive inflammatory breast cancer patient: a case report.
Montagna E; Cancello G; Torrisi R; Rizzo S; Scarano E; Colleoni M
Ann Oncol; 2010 Mar; 21(3):667-668. PubMed ID: 20032127
[No Abstract] [Full Text] [Related]
46. Current combination chemotherapy regimens for metastatic breast cancer.
Schwartz J
Am J Health Syst Pharm; 2009 Dec; 66(23 Suppl 6):S3-8. PubMed ID: 19923317
[TBL] [Abstract][Full Text] [Related]
47. Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study.
Untch M; Rezai M; Loibl S; Fasching PA; Huober J; Tesch H; Bauerfeind I; Hilfrich J; Eidtmann H; Gerber B; Hanusch C; Kühn T; du Bois A; Blohmer JU; Thomssen C; Dan Costa S; Jackisch C; Kaufmann M; Mehta K; von Minckwitz G
J Clin Oncol; 2010 Apr; 28(12):2024-31. PubMed ID: 20308670
[TBL] [Abstract][Full Text] [Related]
48. A rare case of isolated adrenal metastasis of invasive ductal breast carcinoma.
Andjelić-Dekić N; Božović-Spasojević I; Milošević S; Matijašević M; Karadžić K
Srp Arh Celok Lek; 2014; 142(9-10):597-601. PubMed ID: 25518541
[TBL] [Abstract][Full Text] [Related]
49. [A Case of Long-Term Survival of Breast Cancer with Lymph Node and Liver Metastases Treated with Sequential Anti-HER2 Drugs, Chemotherapy, and Endocrine Therapy].
Katsumori T; Ohshima H; Hamaguchi H; Yamamoto S; Tsukamoto Y; Iwanaga T; Ohkawara S
Gan To Kagaku Ryoho; 2017 Nov; 44(12):1838-1840. PubMed ID: 29394793
[TBL] [Abstract][Full Text] [Related]
50. [Efficacy and toxicity of lapatinib plus capecitabine therapy in HER2-positive metastatic breast cancer].
Chiba A; Shimizu S; Yoshida A; Inaba M; Matsuura H; Ino H; Suganuma N; Inari H; Yamanaka T; Kuroda K; Mukaibashi T; Matsuo A; Kojima I
Gan To Kagaku Ryoho; 2012 Nov; 39(11):1675-9. PubMed ID: 23152018
[TBL] [Abstract][Full Text] [Related]
51. Treatment of HER2-positive metastatic breast cancer with lapatinib and capecitabine in the lapatinib expanded access programme, including efficacy in brain metastases--the UK experience.
Sutherland S; Ashley S; Miles D; Chan S; Wardley A; Davidson N; Bhatti R; Shehata M; Nouras H; Camburn T; Johnston SR
Br J Cancer; 2010 Mar; 102(6):995-1002. PubMed ID: 20179708
[TBL] [Abstract][Full Text] [Related]
52. [Successful treatment of trastuzumab-resistant HER2-positive breast cancer with extensive liver metastases using the combination of trastuzumab and capecitabine - a case report].
Shigekawa T; Takeuchi H; Misumi M; Nakamiya N; Sugiyama M; Sugitani I; Fujiuchi N; Osaki A; Saeki T
Gan To Kagaku Ryoho; 2013 Feb; 40(2):225-7. PubMed ID: 23411960
[TBL] [Abstract][Full Text] [Related]
53. Lapatinib or Trastuzumab Plus Taxane Therapy for Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: Final Results of NCIC CTG MA.31.
Gelmon KA; Boyle FM; Kaufman B; Huntsman DG; Manikhas A; Di Leo A; Martin M; Schwartzberg LS; Lemieux J; Aparicio S; Shepherd LE; Dent S; Ellard SL; Tonkin K; Pritchard KI; Whelan TJ; Nomikos D; Nusch A; Coleman RE; Mukai H; Tjulandin S; Khasanov R; Rizel S; Connor AP; Santillana SL; Chapman JA; Parulekar WR
J Clin Oncol; 2015 May; 33(14):1574-83. PubMed ID: 25779558
[TBL] [Abstract][Full Text] [Related]
54. A phase II study of trastuzumab and capecitabine for patients with HER2-overexpressing metastatic breast cancer: Japan Breast Cancer Research Network (JBCRN) 00 Trial.
Yamamoto D; Iwase S; Kitamura K; Odagiri H; Yamamoto C; Nagumo Y
Cancer Chemother Pharmacol; 2008 Mar; 61(3):509-14. PubMed ID: 17516068
[TBL] [Abstract][Full Text] [Related]
55. [Two cases of breast cancer responding to primary systemic chemotherapy containing trastuzumab without surgery].
Konishi K; Hasegawa N; Kaneko H; Iimura Y; Shoji Y; Kawabata M
Gan To Kagaku Ryoho; 2010 Jan; 37(1):115-8. PubMed ID: 20087043
[TBL] [Abstract][Full Text] [Related]
56. [Efficacy of FEC and trastuzumab/docetaxel combination therapy for metastatic breast cancer].
Matsumoto K; Yoshinouchi S; Takano Y; Kanzaki M; Maeda M; Miyoshi S; Wakita T; Teshima S
Gan To Kagaku Ryoho; 2010 Mar; 37(3):503-5. PubMed ID: 20332692
[TBL] [Abstract][Full Text] [Related]
57. [A case of acute appendicitis which occurred during chemotherapy for breast cancer].
Oshida S; Hayashi K; Habiro T; Hatate K; Sengoku N
Gan To Kagaku Ryoho; 2013 Nov; 40(12):2417-9. PubMed ID: 24394131
[TBL] [Abstract][Full Text] [Related]
58. [A Case of Effective Whole-Brain Irradiation and Lapatinib/Capecitabine Combination Therapy for HER2-Positive Breast Cancer with Multiple Brain Metastases].
Shibasaki M; Tanabe A; Toda T; Sakata H; Ijichi M; Kusaka K; Bandai Y
Gan To Kagaku Ryoho; 2015 Jun; 42(6):755-7. PubMed ID: 26199252
[TBL] [Abstract][Full Text] [Related]
59. A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine.
Krop IE; LoRusso P; Miller KD; Modi S; Yardley D; Rodriguez G; Guardino E; Lu M; Zheng M; Girish S; Amler L; Winer EP; Rugo HS
J Clin Oncol; 2012 Sep; 30(26):3234-41. PubMed ID: 22649126
[TBL] [Abstract][Full Text] [Related]
60. Randomized phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastases.
Lin NU; Eierman W; Greil R; Campone M; Kaufman B; Steplewski K; Lane SR; Zembryki D; Rubin SD; Winer EP
J Neurooncol; 2011 Dec; 105(3):613-20. PubMed ID: 21706359
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
